|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |
| Brief Title † | A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter |
| Official Title † | A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter |
| Brief Summary | To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter. |
| Detailed Description | |
| Study Phase | |
| Study Type † | Interventional |
| Study Design † | Prevention, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
| Primary Outcome Measure † | Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. [ Time Frame: 6 months follow-up ] [ Designated as safety issue: Yes ] |
| Secondary Outcome Measure † | The proportion of patients with successful deployment of the filter will be calculated and presented with a 95% exact confidence interval. [ Time Frame: 3 and 6 months follow-up ] [ Designated as safety issue: Yes ] |
| Condition † | Pulmonary Embolism |
| Intervention † | Device: SafeFlo IVC Filter |
| MEDLINE PMIDs | |
| Links | Sponsor Website ![]() |
| Recruitment Information Fields | |
| Recruitment Status † | Active, not recruiting |
| Enrollment † | 117 |
| Start Date † | July 2003 |
| Completion Date | |
| Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
| Gender | Both |
| Ages | 18 Years and older |
| Accepts Healthy Volunteers | No |
| Contacts †† | |
| Location Countries † | United States, Austria, Greece, Israel, South Africa, United Kingdom |
| Administrative Information Fields | |
| NCT ID † | NCT00654979 |
| Organization ID | SFF-104 |
| Secondary IDs †† | |
| Study Sponsor † | RMT Medical Technologies, Ltd. |
| Collaborators †† | |
| Investigators † | |
| Information Provided By | RMT Medical Technologies, Ltd. |
| Verification Date | April 2008 |
| First Received Date † | March 30, 2008 |
| Last Updated Date | April 3, 2008 |